RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Video recording for Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic lateral sclerosis (ALS) is a fatal, rare neurodegenerative disease affecting 30,000 people in the United States. The gold standard of care for people with ALS is multidisciplinary clinics (MDC).

Official registry: https://clinicaltrials.gov/study/NCT07454733 · Trustees of Dartmouth College · enrollment listed as 800

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Video recording, or Notes Instruction. The registry lists allocation as randomized. Amyotrophic lateral sclerosis (ALS) is a fatal, rare neurodegenerative disease affecting 30,000 people in the United States.

They plan to enroll about 800 people at 7 sites. Taking part typically means following a program (exercise, therapy, diet, or an app) plus check-ins.

Official title (unrewritten)

Comparing the Impact of Video Integration to Traditional Amyotrophic Lateral Sclerosis Visit Communication on Patient and Caregiver Quality of Life

Interventions: Video recording, Notes Instruction

Primary outcome (registry wording): For Caregiver Participants: the total score on the PROMIS-10 self report survey

Who it is for (from inclusion criteria)

Ages 18 Years to any
for People with ALS:
Diagnosis of ALS by either El- Escorial or Gold Coast Criteria
Plan to attend MDC visits for 12 months
Presence of a caregiver (defined as someone who assists with care) who is also participating in the VITALS trial
Projected life expectancy of at least 12 months as determined by the site investigator

Who the registry excludes

for People with ALS:
Significant cognitive impairment, clinical dementia, or unstable psychiatric illness (including, but not limited to, psychosis, active suicidal ideation, suicide attempt, or untreated major depression) as determined by the site investigator
Current pregnancy based on participant self-report;
Unable to access the internet;
Do not have access to a personal or shared email and are not interested in creating a personal or shared email;
Do not wish to create a patient portal account, if they do not already have one;
Uncorrected hearing or visual impairment that would impair the ability to view video recordings;

Public study contact (from the registry)

Paul J Barr, PhD

603-646-7016

paul.j.barr@dartmouth.edu

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

7 listed

Mayo Clinic Scottsdale — Scottsdale, Arizona (not_yet_recruiting)
Mayo Clinic Jacksonville — Jacksonville, Florida (not_yet_recruiting)
Massachusetts General Hospital — Boston, Massachusetts (not_yet_recruiting)
Dartmouth-Hitchcock Health — Lebanon, New Hampshire (recruiting)
Penn State Health Milton S. Hersey Medical Center — Hershey, Pennsylvania (not_yet_recruiting)
University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania (not_yet_recruiting)
University of Wisconsin Health — Madison, Wisconsin (not_yet_recruiting)

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland

Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Re…

We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled.

NCT00001238 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phaseBethesda, Maryland

Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia

Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

FAQ about this NCT record

Is NCT07454733 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07454733?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07454733?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary